Welcome to our dedicated page for Candel Therapeutics news (Ticker: CADL), a resource for investors and traders seeking the latest updates and insights on Candel Therapeutics stock.
Candel Therapeutics, Inc. (NASDAQ: CADL) is a clinical-stage biopharmaceutical company at the forefront of developing innovative viral-based immunotherapies to combat cancer. Headquartered in Massachusetts, the company leverages its proprietary multimodal platforms to deliver off-the-shelf therapies that elicit a robust and individualized systemic anti-tumor immune response. Operating within the competitive and rapidly evolving immuno-oncology space, Candel Therapeutics addresses significant unmet medical needs by targeting solid tumors with precision and innovation.
Core Technologies and Platforms
Candel Therapeutics has established two proprietary viral-based immunotherapy platforms designed to revolutionize cancer treatment:
- Gene Mediated Cytotoxic Immunotherapy (GMCI™) Platform: This platform utilizes genetically modified adenoviruses to deliver a localized, tumor-targeted immune response. As an "off-the-shelf" solution, GMCI™ activates the patient’s immune system to generate a personalized and precise response against cancer cells without requiring extensive customization.
- enLIGHTEN™ Discovery Platform: A systematic, iterative platform leveraging herpes simplex virus (HSV) constructs and advanced analytics to create novel viral immunotherapies. This platform is designed to accelerate the discovery and development of therapies for solid tumors, utilizing human biology insights to optimize therapeutic outcomes.
Pipeline and Key Product Candidates
Candel’s product pipeline is anchored by two lead candidates:
- CAN-2409: Developed from the adenovirus platform, this candidate is undergoing clinical trials for multiple indications, including non-small cell lung cancer (NSCLC), borderline resectable pancreatic ductal adenocarcinoma (PDAC), and localized prostate cancer. CAN-2409 aims to address patients who are non-responsive to traditional immune checkpoint inhibitors, providing a novel therapeutic option.
- CAN-3110: Originating from the HSV platform, this candidate is being evaluated in phase 1b trials for recurrent high-grade glioma (rHGG). Designed to treat difficult-to-treat cancers, CAN-3110 demonstrates the potential of HSV-based therapies in addressing aggressive tumor types.
Market Position and Competitive Landscape
Operating within the immuno-oncology sector, Candel Therapeutics competes against established biopharmaceutical giants and emerging innovators. The company differentiates itself through its multimodal approach, combining the benefits of viral-based platforms with advanced analytics and human biology insights. This unique positioning allows Candel to address complex cancers with tailored, systemic solutions that complement existing therapies.
Significance and Industry Impact
Candel Therapeutics’ commitment to developing off-the-shelf, multimodal immunotherapies positions it as a key player in the fight against cancer. By focusing on systemic, individualized immune responses, the company addresses critical gaps in current treatment paradigms. Its innovative platforms and promising clinical results underscore its potential to transform cancer care, making it a noteworthy entity in the biopharmaceutical industry.
Rhea-AI Summary
Candel Therapeutics, a biopharmaceutical company, announced two abstracts accepted for presentation at the 2024 ASCO Annual Meeting. One abstract focuses on a phase 1 clinical trial of CAN-3110 for recurrent high-grade glioma, showcasing feasibility and tolerability. The second abstract presents overall survival data from a phase 2 trial of CAN-2409 plus valacyclovir for NSCLC patients with an inadequate response to front line therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.28%
Tags
-
Rhea-AI Summary
Candel Therapeutics, Inc. (CADL) receives Orphan Drug Designation from the FDA for CAN-2409, a promising multimodal biological immunotherapy candidate for pancreatic cancer. Clinical trial data shows significant improvement in overall survival rates and safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
42.75%
Tags
-
Rhea-AI Summary
Candel Therapeutics, Inc. presents a first-in-class immunotherapy candidate for solid tumors, inducing tertiary lymphoid structures for improved anti-tumor immunity. The candidate, developed from the enLIGHTEN™ Discovery Platform, shows promising results in inhibiting tumor growth and enhancing response to immune checkpoint inhibitors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.84%
Tags
Rhea-AI Summary
Candel Therapeutics (CADL) announces positive interim data showing significant improvements in overall survival in patients with pancreatic cancer treated with CAN-2409. Survival rates at 24 and 36 months were notably higher in the CAN-2409 group compared to the control group. The treatment was well tolerated with no new safety signals observed. The FDA granted Fast Track Designation for CAN-2409 in combination with valacyclovir for pancreatic cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
280.95%
Tags
-
Rhea-AI Summary
Candel Therapeutics, Inc. announces positive data from ongoing phase 1b clinical trial of CAN-3110 for rHGG patients, showing promising results in overall survival and tolerability. The company received FDA Fast Track Designation for CAN-3110 in Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.76%
Tags
-
Rhea-AI Summary
Candel Therapeutics, Inc. reported financial results for Q4 2023, with positive clinical trial outcomes for CAN-2409 in pancreatic cancer and CAN-3110 in high-grade glioma. The company received FDA Fast Track Designations for both treatments, showing improved survival rates compared to standard care. Candel anticipates significant data readouts in 2024 across various cancer platforms, including a potentially registrational phase 3 trial for prostate cancer. Financially, research and development expenses increased due to activities supporting CAN-2409 programs, resulting in a net loss for Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.6%
Tags
Rhea-AI Summary
Candel Therapeutics, Inc. (CADL) will present a poster at the AACR Annual Meeting on a first-in-class immunotherapy candidate for solid tumors, accelerating the unveiling of the second enLIGHTEN™ program. The presentation focuses on inducing tertiary lymphoid structures as a novel therapeutic strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.07%
Tags
-
Rhea-AI Summary
Candel Therapeutics, Inc. (CADL) receives FDA Fast Track Designation for CAN-3110, a promising oncolytic viral immunotherapy candidate for recurrent high-grade glioma. Positive results from the phase 1b clinical trial show a nearly doubled median overall survival with a single injection, highlighting the therapy's potential to address the unmet needs in this therapy-resistant condition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.5%
Tags
-
Rhea-AI Summary
Candel Therapeutics, Inc. (Nasdaq: CADL) has highlighted upcoming milestones, including data readouts in lung, pancreatic, brain, and prostate cancer, as well as recent successes in immunotherapy. The company received Fast Track Designation from the FDA for its product candidate, CAN-2409, and reported positive clinical trial data for CAN-3110. These developments position Candel for progress and differentiation in the cancer therapeutics market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
Rhea-AI Summary
Candel Therapeutics, Inc. (Candel) (Nasdaq: CADL) has been granted Fast Track Designation by the FDA for its lead investigational adenovirus asset CAN-2409 plus prodrug for the treatment of pancreatic ductal adenocarcinoma (PDAC) to improve overall survival. The company presented encouraging overall survival and immunological biomarker data based on an interim analysis of the randomized, phase 2 clinical trial at the Society for Immunotherapy of Cancer (SITC) Annual Meeting. The estimated survival rate of patients who received the CAN-2409 plus prodrug regimen was 71.4% at both 24 and 36 months, compared to only 16.7% in patients treated with standard of care (SoC) chemoradiation prior to surgery alone. Candel remains on track to release updated overall survival data in the second quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.23%
Tags
FAQ
What is the current stock price of Candel Therapeutics (CADL)?
The current stock price of Candel Therapeutics (CADL) is $7.91 as of March 3, 2025.
What is the market cap of Candel Therapeutics (CADL)?
The market cap of Candel Therapeutics (CADL) is approximately 388.3M.
What does Candel Therapeutics, Inc. specialize in?
Candel Therapeutics specializes in developing viral-based immunotherapies to treat cancer, leveraging proprietary platforms to elicit individualized immune responses.
What are Candel Therapeutics’ key platforms?
Candel utilizes two platforms: the GMCI™ platform, based on adenovirus constructs, and the enLIGHTEN™ Discovery Platform, based on HSV constructs.
What are the lead product candidates in Candel’s pipeline?
Candel’s lead candidates are CAN-2409, targeting NSCLC, PDAC, and prostate cancer, and CAN-3110, designed for recurrent high-grade glioma.
How does Candel differentiate itself in the immuno-oncology market?
Candel stands out through its multimodal, off-the-shelf therapies that combine viral-based platforms with advanced analytics to create systemic, individualized cancer treatments.
What challenges does Candel Therapeutics face?
Candel faces challenges such as high R&D costs, regulatory hurdles, and competition from established players in the immuno-oncology space.
What is the significance of Candel’s GMCI™ platform?
The GMCI™ platform uses adenovirus constructs to activate a patient’s immune system, generating a personalized, robust, and precise response against tumors.
What is the enLIGHTEN™ Discovery Platform?
The enLIGHTEN™ platform leverages HSV constructs and advanced analytics to accelerate the discovery and development of novel therapies for solid tumors.
What types of cancers does Candel Therapeutics target?
Candel focuses on solid tumors, including non-small cell lung cancer, pancreatic cancer, prostate cancer, and recurrent high-grade glioma.
What is the business model of Candel Therapeutics?
Candel’s business model is centered on developing and commercializing viral-based immunotherapies, with revenue likely generated through licensing, partnerships, and product sales post-approval.
How does Candel’s approach complement existing cancer therapies?
Candel’s therapies are designed to work alongside existing treatments, addressing patients non-responsive to immune checkpoint inhibitors and targeting difficult-to-treat cancers.
Candel Therapeutics, Inc.
Nasdaq:CADL
CADL Rankings
CADL Stock Data
388.27M
33.68M
30.39%
22.53%
5.55%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
NEEDHAM